Bayer is just the latest in a string of big pharma companies to invest in firms with CRISPR-Cas9 expertise, of which CRISPR Therapeutics is one of four leading players.

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

including a tie-up with Mammoth rival CRISPR Therapeutics way back in 2015. The drive gathered momentum in 2019 with the acquisition of cell therapy player Bluerock Therapeutics, which has since ...

Feng Wei at the Institute of Biophysics, Chinese Academy of Sciences, has made significant strides in understanding the BORC complex, a key player in ... line using CRISPR/Cas9 and confirmed ...

CRISPR Therapeutics uses the CRIPSR-Cas9 technology to edit genes in patients suffering ... in its home domain of genome sequencing but is likely to stay the dominant player with its new generation of ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.